Renowned pediatric endocrinologist and researcher brings deep clinical and technical expertise to expanded leadership role
Glooko, a leading global diabetes data management company, announced the appointment of Dr. Mark Clements as Chief Medical and Strategy Officer. Dr. Clements has served as Glooko’s fractional Chief Medical Officer since 2016 and will step into this expanded, full-time role designed to strategically integrate the company’s clinical vision, product roadmap, and data solutions to accelerate growth and innovation.
Health Technology Insights: SpotitEarly Launches in U.S. with $20Million+ for At-Home Cancer Detection
“Dr. Clements’ expertise as an endocrinologist, coupled with his deep experience in diabetes digital health, remote patient monitoring, data integration, AI and machine learning, and clinical trial design, uniquely positions him to align clinical insights directly with Glooko’s product and service offerings,” said Mike Alvarez, Chief Executive Officer of Glooko. “We are thrilled to have him in this expanded leadership role that will ensure Glooko continues to enhance health outcomes for people with diabetes, drive healthcare efficiencies, and solidify our market leadership through innovation grounded in clinical insight.”
Health Technology Insights: Akido Raises $60Million to Expand ScopeAI Health AI Platform
In addition to his role as Chief Medical Officer of Glooko, Dr. Clements most recently served as Professor of Pediatrics at the University of Missouri-Kansas City (UMKC) School of Medicine, where he held the Endowed Chair in Endocrinology and Diabetes. At UMKC, Dr. Clements also held the role of Medical Director of the Pediatric Clinical Research Unit and the Diabetes Research Program and was Co-Principal Investigator of the TrialNet Clinical Center and Data Science Lead for the Type 1 Diabetes Exchange-Quality Improvement (T1DX-QI) initiative.
“As a long-time advisor to Glooko and an active user of the platform in my clinical practice, I’ve witnessed firsthand how Glooko helps clinical teams consistently deliver measurable improvements in diabetes care outcomes,” said Dr. Clements. “As we look to the future, precision engagement and population health insights will be key focuses of the company and our platform. We are investing in making it easier for healthcare providers to connect people with diabetes to the Glooko platform, reducing clinical staff burden, optimizing clinician time, helping them stay at the top of their scope of practice, and personalizing interventions. This is a pivotal moment for our company and for diabetes care delivery overall, and I am confident Glooko’s best-in-class technology will continue to improve how diabetes care is delivered.”
Health Technology Insights: eClinical Solutions Welcomes Sean Lannan as Chief Financial Officer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
